As additional research becomes available, recommendations related to the use of glucose-lowering agents to optimize glycemic, cardiovascular, and renal outcomes will undoubtedly continue to evolve and inform patient-centered diabetes care
Li G, Xu Q, Cheng D, Sun W, Liu Y, Ma D, et al
The February 2026 Update: Current Status In early February 2026, media outlets reported on the launch of a compounded oral semaglutide pill by Hims & Hers
The BALANCE Model will empower more Americans to live healthier lives by expanding access to GLP-1s that have shown to be a powerful tool against the development of diseases, such as diabetes, cardiovascular disease, and other metabolic conditions, which can negatively affect a persons long-term health, CMMI Director Abe Sutton said in the press release
[4] Some preclinical and early clinical research has explored its potential in contexts involving cerebral ischemia, though much of this evidence is preliminary or derived from Eastern European clinical populations and should be interpreted cautiously